Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Head & Neck 1Gynecologic 1Genitourinary 1Dermatologic 1CNS 1Breast 1

Conditions

Glioblastoma 5Recurrence 3Glioma 3Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 2Neoplasms 1Lymphoma, Follicular 1Lung Neoplasms 1Gliosarcoma 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1Central Nervous System Neoplasms 1

Interventions

Radiotherapy 6Temozolomide 5Flow Cytometry 5Cyclophosphamide 5Therapeutics 4Psychiatric Rehabilitation 4Melphalan 4Magnetic Resonance Spectroscopy 4Filgrastim 4sargramostim 3Specimen Handling 3Polymerase Chain Reaction 3Methylprednisolone 3liposomal amphotericin B 2Topotecan 2Thiotepa 2Rituximab 2Radiotherapy, Intensity-Modulated 2Peripheral Blood Stem Cell Transplantation 2Ondansetron 2Itraconazole 2Immunologic Techniques 2Fentanyl 2Early Intervention, Educational 2Dexamethasone 2Caspofungin 2Carmustine 2Calcium Dobesilate 2Busulfan 2Aprepitant 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Follicular × cemiplimab × CNS × Clear all
NCT04826393 2025-10-22

ASP8374 + Cemiplimab in Recurrent Glioma

Dana-Farber Cancer Institute

Phase 1 Completed
14 enrolled
CNSLymphoid

Glioblastoma, Glioma, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡